Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma
Open accessAbstract
Purpose We researched into the effect and mechanism of AC0010, a novel BTK inhibitor, in MCL, and compared its efficacy and safety with Ibrutinib to develop a preclinical study for the future therapy of MCL.Methods MTS assay was used to detect the growth inhibition caused by AC0010 and Ibrutinib, respectively, in MCL cell lines (Jeko-1 and JVM-2), primary MCL cells, and normal peripheral lymphocytes. Apoptosis of Jeko-1 and JVM-2 after exposure into AC0010 and Ibrutinib was conducted by flow cytometry; the expression of apoptosis-related proteins was checked by Western blot. q-PCR and Western blot were applied to examine the expression of BTK and p-BTK at mRNA and protein level as well as the BTK-ralated signaling pathways. MCL xenograft was developed to testify the efficacy and safety of AC0010 in vivo.Results In contrast with Ibrutinib, AC0010 proved to be more toxic to MCL cells in vitro (p < 0.01) with no augment in cytotoxicity to normal peripheral lymphocytes, and it can induce obvious apoptosis in MCL cell lines (p < 0.01) through caspase family and Bcl-2 family. AC0010 at 300 mg/kg can prolong the survival rate in MCL xenograft (p < 0.01). The phosphorylation of BTK is inhibited by AC0010 following simultaneously inhibition of BCR-BTK and PI3K/AKT signaling pathway in MCL cells.Conclusion AC0010 is a novel BTK inhibitor of great efficacy and safety in MCL.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The IC50 of avitinib for EGFRL858R/T790M double mutant was 0.18 nM.
“Moreover, the IC50 for EGFRL858R/T790M double mutant was 0.18 nM.159,160”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831 · see citing works
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685 · see citing works
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561 · see citing works
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326 · see citing works
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · see citing works
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 690 · see citing works
Targeting pathological B cell receptor signalling in lymphoid malignancies
Young, R. M., & Staudt, L. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3937 · Cited by 400 · see citing works
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Pérez‐Galán, P., Dreyling, M. H., & Wiestner, A. U. (2010) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394 · see citing works
Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2013) · American Journal of Hematology · doi:10.1002/ajh.23615 · Cited by 327 · see citing works
Herman, S. E. M., Mustafa, R. Z., Gyamfi, J., Pittaluga, S., Chang, S., Chang, B. Y., Farooqui, M. Z. H., & Wiestner, A. U. (2014) · Blood · doi:10.1182/blood-2014-02-548610 · Cited by 246 · see citing works
Woyach, J. A., Bojnik, E., Ruppert, A. S., Stefanovski, M. R., Goettl, V. M., Smucker, K. A., Smith, L. L., Dubovsky, J. A., Towns, W. H., MacMurray, J., et al. (2013) · Blood · doi:10.1182/blood-2013-07-515361 · Cited by 222 · see citing works
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Buggy, J. J., & Elias, L. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.664797 · Cited by 213 · see citing works
Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24797 · Cited by 209 · see citing works
Chang, B. Y., Francesco, M. R., de Rooij, M. F. M., Magadala, P., Steggerda, S. M., Huang, M. M., Kuil, A., Herman, S. E. M., Chang, S., Pals, S. T., et al. (2013) · Blood · doi:10.1182/blood-2013-02-482125 · Cited by 203 · see citing works
de Claro, R. A., McGinn, K. M., Verdun, N. C., Lee, S., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C., Fletcher, E. P., Habtemariam, B. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2225 · Cited by 174 · see citing works
Cinar, M., Hamedani, F. S., Mo, Z., Cinar, B., Amin, H. M., & Alkan, S. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.028 · Cited by 130 · see citing works
Sharma, S., Orlowski, G. M., & Song, W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.329 · Cited by 126 · see citing works
Wiestner, A. U. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4281 · Cited by 125 · see citing works
de Weers, M., Mensink, R. G. J., Kraakman, M. E. M., Schuurman, R. K. B., & Hendriks, R. W. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.1.161 · Cited by 123 · see citing works
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, N. L., Burger, J. A., & Wodarz, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409362111 · Cited by 98 · see citing works
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90 · see citing works
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87 · see citing works
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Kaur, V., & Swami, A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2973-2 · Cited by 67 · see citing works
Lymphoma classification update: B-cell non-Hodgkin lymphomas
Jiang, M., Bennani, N. N., & Feldman, A. L. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1318053 · Cited by 66 · see citing works
Bernard, S., Danglade, D., Gardano, L., Laguillier, C., Lazarian, G., Roger, C., Thiéblemont, C., Marzec, J., Gribben, J. G., Cymbalista, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29326 · Cited by 52 · see citing works
Cyclin D1 over expression in malignant lymphomas
Nakamura, S., Yatabe, Y., & Seto, M. (1997) · Pathology International · doi:10.1111/j.1440-1827.1997.tb04519.x · Cited by 52 · see citing works
Altered Apoptosis Pathways in Mantle Cell Lymphoma
Rummel, M., de Vos, S., Hoelzer, D. F., Koeffler, H. P., & Hofmann, W. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000151112 · Cited by 43 · see citing works
Molecular Targeted Approaches in Mantle Cell Lymphoma
Weniger, M. A., & Wiestner, A. U. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2011.05.001 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Self-citationBim- and Bax-mediated mitochondrial pathway dominates abivertinib-induced apoptosis and ferroptosis
Tang, Q., Chen, H., Mai, Z., Sun, H., Xu, L., Wu, G., Tu, Z., Cheng, X., Wang, X., & Chen, T. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.013 · Cited by 45 · see citing works
Huang, S., Yu, M., Shi, N., Zhou, Y., Li, F., Li, X., Huang, X., & Jin, J. (2020) · Journal of Cancer · doi:10.7150/jca.34981 · Cited by 30 · see citing works
“Our earlier studies also demonstrated that the novel BTK inhibitor Abivertinib is effective in inhibiting MCL survival (4).”
BackgroundSelf-citationHuang, S., Pan, J., Jin, J., Li, C.-Y., Li, X., Huang, J., Huang, X., Xiao, Y., Li, F., Yu, M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.008 · Cited by 27 · see citing works
Self-citationAbivertinib inhibits megakaryocyte differentiation and platelet biogenesis
Huang, J., Huang, X., Li, Y., Li, X., Wang, J., Li, F., Xiao, Y., Wang, H., Wang, Y., Lin, X., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0838-5 · Cited by 13 · see citing works
“Our previous study shows that abivertinib can effectively inhibit MCL and AML cell growth by attenuating the BCR–Btk pathway [16,19].”
BackgroundMethodSelf-citationIbrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation
Huang, J., Huang, S., Ma, Z., Lin, X., Li, X., Huang, X., Wang, J., Ye, W., Li, Y., He, D., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1716530 · Cited by 10 · see citing works
Self-citationAntifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
Miao, Y., Wang, Y., Bi, Z., Huang, K., Gao, J., Li, X., Li, S., Wei, L., Zhou, H., & Yang, C. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02385-9 · Cited by 8 · see citing works
“In addition, avitinib also acts as a novel Bruton’s tyrosine kinase (BTK) inhibitor, which inhibits the phosphorylation of BTK and the PI3K/Akt signalling pathway in mononuclear cell leukaemia (MCL) cells [20].”
BackgroundResultSelf-citationHuang, S., Li, C., Zhang, X., Pan, J., Li, F., Lv, Y., Huang, J., Ling, Q., Ye, W., Mao, S., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12742 · Cited by 7 · see citing works
Self-citationYu, T., Han, S., Wang, L., Wang, H., Ni, X., Wang, R., Li, G., Hou, Y., Peng, J., Yan, Z., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20045 · Cited by 7 · see citing works
“31,32 Meanwhile, BTK activation represses the Fas–FasL pathway, which is necessary for the negative selection of B cells.”
Zhang, X., Yang, H., Nie, Y., Jiang, Y., Sui, X., Ge, X., Liu, F., Zhang, Y., & Wang, X. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02313-8 · Cited by 3 · see citing works
“1 3 lymphomas, the therapeutic regimens for MCL are more intensive [7].”
BackgroundMiao, Y., Wang, Y., Bi, Z., Huang, K., Gao, J., Li, X., Li, S., Wei, L., Zhou, H., & Yang, C. (2023) · Figshare · doi:10.6084/m9.figshare.22623265
Self-citationMiao, Y., Wang, Y., Bi, Z., Huang, K., Gao, J., Li, X., Li, S., Wei, L., Zhou, H., & Yang, C. (2023) · Figshare · doi:10.6084/m9.figshare.22623271
Self-citationMiao, Y., Wang, Y., Bi, Z., Huang, K., Gao, J., Li, X., Li, S., Wei, L., Zhou, H., & Yang, C. (2023) · Figshare · doi:10.6084/m9.figshare.22623274
Self-citation
- Authors
- Yan, X., Zhou, Y., Huang, S., Li, X., Yu, M., Huang, J., Wang, J., Ma, Z., Jin, J., Pan, J., Li, C., Li, F., & Jin, J.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Corresponding author
- Jin, Jingrui
- Jin, Jie
- ORCID
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2018-02-01
- Volume
- 144
- Issue
- 4
- Pages
- 697-706
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- PMC
- PMC11813394
- OpenAlex
- W2786933192
- Cited by
- 12
- References
- 29
- Citations by year
- 2025: 1 · 2023: 5 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Cancer Research and Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81370643, 81470305, 81670124)
- Zhejiang Provincial Key Innovation Team (2011R50015)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- BTK inhibitors, mantle cell lymphoma, ibrutinib, apoptosis, caspases, Bcl-2 family proteins, BTK phosphorylation, PI3K/Akt signaling, B cell receptor signaling, xenografts, cytotoxicity
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Animals, Female, Humans, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Mice, SCID, Lymphoma, Mantle-Cell, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
